The proposed therapy involves a combination of mezigdomide, carfilzomib, and dexamethasone. Mezigdomide belongs to a novel class of drugs known as cereblon E3 ligase modulators, or CELMoDs. These agents operate by binding to cereblon, a protein integral to the body's natural waste-disposal system, to trigger the degradation of proteins that drive cancer growth.

This regulatory progress follows the ongoing review of iberdomide, another CELMoD agent in the Bristol Myers pipeline. With a target decision date of August 17, iberdomide could become the first drug in this class to receive FDA approval, potentially setting the stage for the broader adoption of this mechanism in oncology.